Table 4.
Survivor (n = 182) | Non survivor (n = 52) | P value | |||
---|---|---|---|---|---|
All patients (n = 234) |
Empirical |
Combination |
31 (17.0%) |
7 (13.5%) |
0.74 |
|
Monotherapy |
78 (42.9%) |
25 (48.1%) |
|
|
|
Inappropriate |
31 (17.0%) |
7 (13.5%) |
|
|
Targeted |
Combination |
36 (19.8%) |
6 (11.5%) |
0.31 |
|
|
Monotherapy |
109 (59.9%) |
32 (61.5%) |
|
|
|
Inappropriate |
37 (20.3%) |
14 (26.9%) |
|
|
Patients with neutropenia (n = 54) |
Empirical |
Combination |
19 (52.7%) |
4 (22.2%) |
0.001 |
|
Monotherapy |
16 (44.4%) |
7 (38.8%) |
|
|
|
Inadequate |
1 (2.7%) |
7 (38.8%) |
|
|
Targeted |
Combination |
21 (58.3%) |
10 (55.5%) |
0.01 |
|
|
Monotherapy |
14 (38.8%) |
3 (16.7%) |
|
|
Inadequate | 1 (2.7%) | 5 (27.7%) |